Skip to main content
Top
Published in: Clinical & Experimental Metastasis 3/2020

01-06-2020 | Metastasis | Research Paper

Laser interstitial thermal therapy for in-field recurrence of brain metastasis after stereotactic radiosurgery: does treatment with LITT prevent a neurologic death?

Authors: Joel Kaye, Nitesh V. Patel, Shabbar F. Danish

Published in: Clinical & Experimental Metastasis | Issue 3/2020

Login to get access

Abstract

Brain metastasis (BM) affects up to one-third of adults with cancer and carries a historically bleak prognosis. Despite advances in stereotactic radiosurgery (SRS), rates of in-field recurrence (IFR) after SRS range from 10 to 25%. High rates of neurologic death have been reported after SRS failure, particularly for recurrences deep in the brain and surgically inaccessible. Laser interstitial thermal therapy (LITT) is an emerging option in this setting, but its ability to prevent a neurologic death is unknown. In this study, we investigate the causes of death among patients with BM who undergo LITT for IFR after SRS. We conducted a single institution retrospective case series of patients with BM who underwent LITT for IFR after SRS. Clinical and demographic data were collected via chart review. The primary endpoint was cause of death. Between 2010 and 2018, 70 patients with BM underwent LITT for IFR after SRS. Median follow-up after LITT was 12.0 months. At analysis, 49 patients died; a cause was determined in 44. Death was neurologic in 20 patients and non-neurologic in 24. The 24-month cumulative incidence of neurologic and non-neurologic death was 35.1% and 38.6%, respectively. Etiologies of neurologic death included local recurrence (n = 7), recovery failure (n = 7), distant progression (n = 5), and other (n = 1). Among our patient population, LITT provided the ability to stabilize neurologic disease in up to 2/3 of patients. For IFR after SRS, LITT may represent a reasonable treatment strategy for select patients. Additional work is necessary to determine the extent to which LITT can prevent neurologic death after recurrence of BM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Badiyan SN, Regine WF, Mehta M (2016) Stereotactic radiosurgery for treatment of brain metastases. J Oncol Pract 12(8):703–712CrossRef Badiyan SN, Regine WF, Mehta M (2016) Stereotactic radiosurgery for treatment of brain metastases. J Oncol Pract 12(8):703–712CrossRef
2.
go back to reference Sneed PK et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123(2):373–386CrossRef Sneed PK et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123(2):373–386CrossRef
3.
go back to reference Aoyama H et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491CrossRef Aoyama H et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491CrossRef
4.
go back to reference Lucas JT Jr et al (2015) Competing risk analysis of neurologic versus nonneurologic death in patients undergoing radiosurgical salvage after whole-brain radiation therapy failure: who actually dies of their brain metastases? Int J Radiat Oncol Biol Phys 92(5):1008–1015CrossRef Lucas JT Jr et al (2015) Competing risk analysis of neurologic versus nonneurologic death in patients undergoing radiosurgical salvage after whole-brain radiation therapy failure: who actually dies of their brain metastases? Int J Radiat Oncol Biol Phys 92(5):1008–1015CrossRef
5.
go back to reference Ahluwalia M et al (2018) Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg 130(3):804–811CrossRef Ahluwalia M et al (2018) Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg 130(3):804–811CrossRef
6.
go back to reference Hernandez RN et al (2018) Magnetic resonance-guided laser-induced thermal therapy for the treatment of progressive enhancing inflammatory reactions following stereotactic radiosurgery, or peirs, for metastatic brain disease. Neurosurgery 85(1):84–90CrossRef Hernandez RN et al (2018) Magnetic resonance-guided laser-induced thermal therapy for the treatment of progressive enhancing inflammatory reactions following stereotactic radiosurgery, or peirs, for metastatic brain disease. Neurosurgery 85(1):84–90CrossRef
7.
go back to reference McKay WH et al (2016) Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery. J Neurosurg 127(1):148CrossRef McKay WH et al (2016) Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery. J Neurosurg 127(1):148CrossRef
8.
go back to reference Hong CS et al (2019) Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery. J Neurooncol 142(2):309–317CrossRef Hong CS et al (2019) Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery. J Neurooncol 142(2):309–317CrossRef
9.
go back to reference Chaunzwa TL et al (2018) Laser thermal ablation for metastases failing radiosurgery: a multicentered retrospective study. Neurosurgery 82(1):56–63CrossRef Chaunzwa TL et al (2018) Laser thermal ablation for metastases failing radiosurgery: a multicentered retrospective study. Neurosurgery 82(1):56–63CrossRef
10.
go back to reference Salehi A et al (2018) Management of intracranial metastatic disease with laser interstitial thermal therapy. Front Oncol 8:499CrossRef Salehi A et al (2018) Management of intracranial metastatic disease with laser interstitial thermal therapy. Front Oncol 8:499CrossRef
11.
go back to reference McTyre ER et al (2017) Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol 19(4):558–566PubMed McTyre ER et al (2017) Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol 19(4):558–566PubMed
12.
go back to reference Patel PD et al (2016) The role of MRgLITT in overcoming the challenges in managing infield recurrence after radiation for brain metastasis. Neurosurgery 79(Suppl 1):S40–S58CrossRef Patel PD et al (2016) The role of MRgLITT in overcoming the challenges in managing infield recurrence after radiation for brain metastasis. Neurosurgery 79(Suppl 1):S40–S58CrossRef
13.
go back to reference Jethwa PR et al (2012) Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 71(1 Suppl Operative):133–44; 144–145CrossRef Jethwa PR et al (2012) Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 71(1 Suppl Operative):133–44; 144–145CrossRef
14.
go back to reference Patchell RA et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489CrossRef Patchell RA et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489CrossRef
15.
go back to reference Iorio-Morin C et al (2019) Repeat stereotactic radiosurgery for the management of locally recurrent brain metastases. J Neurooncol 145(3):551–559CrossRef Iorio-Morin C et al (2019) Repeat stereotactic radiosurgery for the management of locally recurrent brain metastases. J Neurooncol 145(3):551–559CrossRef
16.
go back to reference Minniti G et al (2016) Repeated stereotactic radiosurgery for patients with progressive brain metastases. J Neurooncol 126(1):91–97CrossRef Minniti G et al (2016) Repeated stereotactic radiosurgery for patients with progressive brain metastases. J Neurooncol 126(1):91–97CrossRef
17.
go back to reference Kim IY et al (2018) Repeat stereotactic radiosurgery for recurred metastatic brain tumors. J Korean Neurosurg Soc 61(5):633–639CrossRef Kim IY et al (2018) Repeat stereotactic radiosurgery for recurred metastatic brain tumors. J Korean Neurosurg Soc 61(5):633–639CrossRef
18.
go back to reference Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29(2):134–141CrossRef Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29(2):134–141CrossRef
Metadata
Title
Laser interstitial thermal therapy for in-field recurrence of brain metastasis after stereotactic radiosurgery: does treatment with LITT prevent a neurologic death?
Authors
Joel Kaye
Nitesh V. Patel
Shabbar F. Danish
Publication date
01-06-2020
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 3/2020
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-020-10035-1

Other articles of this Issue 3/2020

Clinical & Experimental Metastasis 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine